Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation.
AUTOR(ES)
Ricciardi, R
RESUMO
The effectiveness of intranasal neostigmine (9.3-13.8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1014678Documentos Relacionados
- Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
- Single fibre electromyographic studies in myasthenia gravis with repetitive nerve stimulation.
- THE INTRA-ARTERIAL INJECTION OF NEOSTIGMINE AS A DIAGNOSTIC TEST IN MYASTHENIA GRAVIS
- Worsening of myasthenia gravis on treatment with imipenem/cilastatin.
- Clinical electrophysiology in myasthenia gravis.
